Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. It also develops REL-P11, a modified-release formulation of psilocybin that has completed Phase 1 safety study for the treatment of metabolic disease. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Metrics to compare | RLMD | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRLMDPeersSector | |
---|---|---|---|---|
P/E Ratio | −0.3x | −4.4x | −0.5x | |
PEG Ratio | −0.01 | 0.00 | 0.00 | |
Price/Book | 1.2x | 2.7x | 2.6x | |
Price / LTM Sales | - | 1.7x | 3.3x | |
Upside (Analyst Target) | 70.1% | 69.4% | 40.3% | |
Fair Value Upside | Unlock | 10.1% | 4.7% | Unlock |